Background: Autologous stem-cell transplantation (ASCT) is established lymphoma therapy, but the procedure has a substantial treatment-related mortality. Methods All 433 lymphoma patients who underwent ASCT at Karolinska Huddinge 1994-2016 were investigated, including long- and short-term mortality, causes of death, longitudinal laboratory values and anti-lymphoma treatments, harvested and transplanted CD34 cell amounts, infectious and other complications, microbiology findings, intensive care, drugs administered, chemotherapy-induced nausea, hospital stay, and secondary myeloid neoplasia. Findings: BEAM was the conditioning for 93%. The 100-day overall and non-lymphoma mortality were 7·2% and 5·6%. Stem cell harvests